Anticancer Ruthenium Complexes with HDAC Isoform Selectivity
(2020)
Journal Article
The histone deacetylase (HDAC) enzymes have emerged as an important class of molecular targets in cancer therapy, with five inhibitors in clinical use. Recently, it has been shown that a lack of selectivity between the 11 Zn-dependent HDAC isoforms m... Read More about Anticancer Ruthenium Complexes with HDAC Isoform Selectivity.